查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654232

美國人類原代細胞培養市場規模、佔有率、趨勢分析報告：按產品、應用、最終用途和細分市場預測，2025-2030 年

U.S. Human Primary Cell Culture Market Size, Share & Trends Analysis Report By Product (Primary Cells, Primary Cell Culture Media), By Application, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國人類原代細胞培養市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，美國人類原代細胞培養市場規模預計到2030年將達到25.8億美元，預測期間的複合年成長率為10.5%。

這一成長是由精準醫療需求的不斷成長、細胞培養技術的進步以及藥物發現、再生醫學和個人化醫療應用的不斷增加所推動的。

腫瘤學和再生醫學領域日益增多的應用正在推動市場成長。原代細胞培養透過提供精確的模型來研究腫瘤行為和藥物反應，在癌症研究中發揮至關重要的作用。在再生醫學中，它對於幹細胞療法、組織工程和再生治療的發展至關重要。它能夠忠實地模擬人體生理學，使其成為提高研究效率、推動癌症治療和個人化醫療的重要工具，進一步刺激了市場的擴張。這將推動預測期內美國對人類原代細胞培養的需求。

由於迫切需要精確的模型來研究 SARS-CoV-2 以及開發疫苗和治療方法，COVID-19 疫情大大增加了美國市場對人類原代細胞培養物的需求。原代細胞培養在病毒研究和藥物開發中已變得至關重要，可以更可靠地模擬人類反應。需求的激增，加上對生物醫學研究的投資不斷增加，加速了原代細胞培養的採用，使其成為即時和長期醫療解決方案的關鍵工具。

然而，原代細胞培養基、試劑和專用設備的高成本帶來了重大的市場挑戰。這些成本可能會限制原代細胞培養的採用，特別是在預算有限的小型研究機構和生物技術公司。對高品質耗材的持續需求和細胞培養系統的複雜設置進一步增加了營運成本，使得資源較匱乏的實驗室難以充分利用這些技術。這種成本障礙可能會減緩市場成長並減少獲得先進研究模型的機會。

美國人類原代細胞培養市場報告重點

  • 2024 年，原發細胞部分佔據最大的市場佔有率，為 35.08%。這是因為它們在各種研究應用中發揮著至關重要的作用，包括藥物發現、毒性測試和個人化醫療開發。然而，預計在預測期內，原代細胞培養基的複合年成長率將最快。
  • 由於原代細胞培養在藥物開發、個人化治療和標靶治療的進步中的應用越來越多，治療方法開發領域在 2024 年佔據了應用市場的主導地位。然而，再生醫學預計在預測期內將以最快的複合年成長率成長。
  • 製藥和生物技術公司部門在最終用途部門佔據主導地位，2024 年的佔有率最大，為 49.27%。然而，預計預測期內 CMO 和 CRO 將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國人類原代細胞培養市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章美國人類原代細胞培養市場：按產品分類的估計和趨勢分析

  • 產品細分儀表板
  • 美國人類原代細胞培養市場的產品差異分析
  • 2018 年至 2030 年美國人類原代細胞培養市場規模及產品趨勢分析
  • 原代細胞
    • 原代細胞市場，2018 - 2030
    • 造血細胞
    • 皮膚細胞
    • 肝細胞
    • 消化道細胞
    • 肺細胞
    • 腎臟細胞
    • 心臟細胞
    • 骨骼細胞和肌肉細胞
    • 其他原代細胞
  • 試劑和補充劑
    • 試劑和補充劑市場，2018-2030 年
    • 無血清培養基
    • 含血清培養基
    • 其他
  • 原代細胞培養基
    • 2018 年至 2030 年原代細胞培養基市場
    • 附件解決方案
    • 緩衝液和鹽
    • 形成
    • 生長因子和細胞激素
    • 其他

第 5 章美國人類原代細胞培養市場：按應用的估計和趨勢分析

  • 應用程式細分儀表板
  • 美國人類原代細胞培養市場使用趨勢分析
  • 2018 年至 2030 年美國人類原代細胞培養市場規模及應用趨勢分析
  • 藥物研發
    • 2018 至 2030 年藥物研發市場
  • 治療方法進展
    • 治療方法開發市場，2018 - 2030 年
  • 再生醫學
    • 再生醫學市場，2018 - 2030
  • 其他
    • 其他市場，2018-2030

第6章美國人類原代細胞培養市場依最終用途、估計和趨勢分析

  • 最終用途細分儀表板
  • 美國人類原代細胞培養市場最終用途變化分析
  • 2018 年至 2030 年美國人類原代細胞培養市場規模及趨勢分析（依最終用途）
  • 製藥及生技公司
    • 2018-2030 年製藥與生技市場
  • CMO 和 CRO
    • CMO 與 CRO 市場，2018 年至 2030 年
  • 學術研究所
    • 學術研究市場，2018-2030

第7章 競爭格局

  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Lonza Group
    • Corning Incorporated
    • Danaher Corporation
    • QIAGEN NV
    • STEMCELL Technologies
    • Becton, Dickinson, and Company（BD）
    • Bio-Techne Corporation
    • Charles River Laboratories
Product Code: GVR-4-68040-501-4

U.S. Human Primary Cell Culture Market Growth & Trends:

The U.S. human primary cell culture market size is anticipated to reach USD 2.58 billion by 2030 and is anticipated to expand at a CAGR of 10.5% during the forecast period, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for precision medicine, advancements in cell culture technologies, and rising applications in drug discovery, regenerative medicine, and personalized healthcare.

The expanding applications in oncology and regenerative medicine are driving market growth. Primary cell cultures play a crucial role in cancer research by providing accurate models for studying tumor behavior and drug responses. In regenerative medicine, they are essential for developing stem cell therapies, tissue engineering, and regenerative treatments. Their ability to closely mimic human physiology enhances research efficiency, making them indispensable tools in advancing cancer therapies and personalized treatments, further fueling the market's expansion. Thereby propelling the demand for human primary cell culture in the U.S. over the forecast period.

The COVID-19 pandemic substantially boosted the demand for human primary cell culture in the U.S. market, driven by the urgent need for accurate models to study SARS-CoV-2 and develop vaccines and therapeutic treatments. Primary cell cultures became essential in virus research and drug development, enabling more reliable simulations of human responses. This surge in demand, coupled with increased investments in biomedical research, accelerated the adoption of primary cell cultures, positioning them as a key tool in both immediate and long-term healthcare solutions.

However, the high costs associated with primary cell culture media, reagents, and specialized equipment pose a significant market challenge. These expenses can limit the adoption of primary cell cultures, especially among smaller research institutions and biotech companies with constrained budgets. The ongoing need for premium-quality supplies and the complex setup for cell culture systems can further increase operational costs, making it difficult for less-funded entities to fully leverage these technologies. This cost barrier could slow the market's growth and reduce accessibility to advanced research models.

U.S. Human Primary Cell Culture Market Report Highlights:

  • The primary cells segment held the largest market share of 35.08% in 2024. This is attributed to their essential role in drug discovery, toxicity testing, and personalized medicine development across various research applications. However, primary cell culture media is anticipated to grow at the fastest CAGR over the forecast period
  • The therapy development segment dominated the application market in 2024, driven by the increasing use of primary cell cultures in drug development, personalized treatments, and the advancement of targeted therapies. However, regenerative medicine is anticipated to grow at the fastest CAGR over the forecast period
  • The pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 49.27% in 2024. However, CMOs & CROs are expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic and infectious diseases
      • 3.2.1.2. Growing focus on personalized medicine
      • 3.2.1.3. Technological innovations in 3D cell culture
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs of primary cells
  • 3.3. U.S. Human Primary Cell Culture Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Human Primary Cell Culture Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Human Primary Cell Culture Market Product Movement Analysis
  • 4.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Primary Cells
    • 4.4.1. Primary Cells Market, 2018 - 2030 (USD Million)
    • 4.4.2. Hematopoietic Cells
      • 4.4.2.1. Hematopoietic Cells Market, 2018 - 2030 (USD Million)
    • 4.4.3. Skin Cells
      • 4.4.3.1. Skin Cells Market, 2018 - 2030 (USD Million)
    • 4.4.4. Hepatocytes
      • 4.4.4.1. Hepatocytes Market, 2018 - 2030 (USD Million)
    • 4.4.5. Gastrointestinal Cells
      • 4.4.5.1. Gastrointestinal Cells Market, 2018 - 2030 (USD Million)
    • 4.4.6. Lung Cells
      • 4.4.6.1. Lung Cells Market, 2018 - 2030 (USD Million)
    • 4.4.7. Renal Cells
      • 4.4.7.1. Renal Cells Market, 2018 - 2030 (USD Million)
    • 4.4.8. Heart Cells
      • 4.4.8.1. Heart Cells Market, 2018 - 2030 (USD Million)
    • 4.4.9. Skeletal and Muscle Cells
      • 4.4.9.1. Skeletal and Muscle Cells Market, 2018 - 2030 (USD Million)
    • 4.4.10. Other Primary Cells
      • 4.4.10.1. Other Primary Cells Market, 2018 - 2030 (USD Million)
  • 4.5. Reagents & Supplements
    • 4.5.1. Reagents & Supplements Market, 2018 - 2030 (USD Million)
    • 4.5.2. Serum-free Media
      • 4.5.2.1. Serum-free Media Market, 2018 - 2030 (USD Million)
    • 4.5.3. Serum-containing Media
      • 4.5.3.1. Serum-containing Media Market, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.6. Primary Cell Culture Media
    • 4.6.1. Primary Cell Culture Media Market, 2018 - 2030 (USD Million)
    • 4.6.2. Attachment Solutions
      • 4.6.2.1. Attachment Solutions Market, 2018 - 2030 (USD Million)
    • 4.6.3. Buffers and Salts
      • 4.6.3.1. Buffers and Salts Market, 2018 - 2030 (USD Million)
    • 4.6.4. Sera
      • 4.6.4.1. Sera Market, 2018 - 2030 (USD Million)
    • 4.6.5. Growth Factors and Cytokines
      • 4.6.5.1. Growth Factors and Cytokines Market, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Human Primary Cell Culture Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. Human Primary Cell Culture Market Application Movement Analysis
  • 5.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery Market, 2018 - 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy Development Market, 2018 - 2030 (USD Million)
  • 5.6. Regenerative Medicine
    • 5.6.1. Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Human Primary Cell Culture Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. U.S. Human Primary Cell Culture Market End Use Movement Analysis
  • 6.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.5. CMOs & CROs
    • 6.5.1. CMOs & CROs Market, 2018 - 2030 (USD Million)
  • 6.6. Academic Research Institutes
    • 6.6.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Profiles/Listing
    • 7.3.1. Thermo Fisher Scientific, Inc.
      • 7.3.1.1. Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Product Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Merck KGaA
      • 7.3.2.1. Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Product Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Lonza Group
      • 7.3.3.1. Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Product Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Corning Incorporated
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Danaher Corporation
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. QIAGEN N.V.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. STEMCELL Technologies
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Becton, Dickinson, and Company (BD)
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Bio-Techne Corporation
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Charles River Laboratories
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives

List of Tables

  • TABLE 1. U.S. human primary cell culture market estimates & forecasts
  • TABLE 2. U.S. human primary cell culture market estimates & forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 3. U.S. human primary cell culture market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 4. U.S. human primary cell culture market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 PESTLE Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 Strategy framework
  • Fig. 13 Participant categorization
  • Fig. 14 U.S. human primary cell culture market: Product outlook key takeaways
  • Fig. 15 U.S. human primary cell culture market: Product movement analysis
  • Fig. 16 Primary cells market, 2018 - 2030 (USD Million)
  • Fig. 17 Hematopoietic cells market, 2018 - 2030 (USD Million)
  • Fig. 18 Skin cells market, 2018 - 2030 (USD Million)
  • Fig. 19 Hepatocytes market, 2018 - 2030 (USD Million)
  • Fig. 20 Gastrointestinal cells market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung cells market, 2018 - 2030 (USD Million)
  • Fig. 22 Renal cells market, 2018 - 2030 (USD Million)
  • Fig. 23 Heart cells market, 2018 - 2030 (USD Million)
  • Fig. 24 Skeletal and muscle cells market, 2018 - 2030 (USD Million)
  • Fig. 25 Other primary cells market, 2018 - 2030 (USD Million)
  • Fig. 26 Primary cell culture media market, 2018 - 2030 (USD Million)
  • Fig. 27 Serum-free media market, 2018 - 2030 (USD Million)
  • Fig. 28 Serum-containing media market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Reagents and supplements market, 2018 - 2030 (USD Million)
  • Fig. 31 Attachment solutions market, 2018 - 2030 (USD Million)
  • Fig. 32 Buffers and salts market, 2018 - 2030 (USD Million)
  • Fig. 33 Sera market, 2018 - 2030 (USD Million)
  • Fig. 34 Growth factors and cytokines market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. human primary cell culture market: Application outlook key takeaways
  • Fig. 37 U.S. human primary cell culture market: Application movement analysis
  • Fig. 38 Drug discovery market, 2018 - 2030 (USD Million)
  • Fig. 39 Therapy development market, 2018 - 2030 (USD Million)
  • Fig. 40 Regenerative medicines market, 2018 - 2030 (USD Million)
  • Fig. 41 Others market, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. human primary cell culture market: End use outlook key takeaways
  • Fig. 43 U.S. human primary cell culture market: End use movement analysis
  • Fig. 44 Pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
  • Fig. 45 CMOs & CROs, 2018 - 2030 (USD Million)
  • Fig. 46 Academic research institutes, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. human primary cell culture market, 2018 - 2030 (USD Million)
  • Fig. 48 Key companies profiled